Abstract
Small molecular weight substances are functional, as neurotrophic factors can be developed as therapeutic drugs to treat neurodegenerative disorder. Recently, a large number of natural and synthetic neuritogenic compounds have been discovered. These compounds have various structural features, including terpenoids, lipids, alkaloids, steroid glycosides, small molecular peptides, and so on. Some of them possess not only neurotrophic properties but also neuroprotective activities. The structure-activity relationships (SARs) and mechanism of action of some important compounds have been studied intensively. Increasing experimental evidence suggests that several of these compounds can be promising candidates for drug development.
Keywords: Neuritogenic substance, Alzheimer's disease, natural products, neurotrophic factors, nerve growth factor, neuronal cells, Aging, SARs, drug development, neuroprotective, terpenoids
Mini-Reviews in Medicinal Chemistry
Title: Structural Diversity of Neuritogenic Substances and their Application Perspective
Volume: 11 Issue: 8
Author(s): J. Qi, Y. Luo and L. Gao
Affiliation:
Keywords: Neuritogenic substance, Alzheimer's disease, natural products, neurotrophic factors, nerve growth factor, neuronal cells, Aging, SARs, drug development, neuroprotective, terpenoids
Abstract: Small molecular weight substances are functional, as neurotrophic factors can be developed as therapeutic drugs to treat neurodegenerative disorder. Recently, a large number of natural and synthetic neuritogenic compounds have been discovered. These compounds have various structural features, including terpenoids, lipids, alkaloids, steroid glycosides, small molecular peptides, and so on. Some of them possess not only neurotrophic properties but also neuroprotective activities. The structure-activity relationships (SARs) and mechanism of action of some important compounds have been studied intensively. Increasing experimental evidence suggests that several of these compounds can be promising candidates for drug development.
Export Options
About this article
Cite this article as:
Qi J., Luo Y. and Gao L., Structural Diversity of Neuritogenic Substances and their Application Perspective, Mini-Reviews in Medicinal Chemistry 2011; 11 (8) . https://dx.doi.org/10.2174/138955711796268796
DOI https://dx.doi.org/10.2174/138955711796268796 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Symmetry-Based Self-Assembled Nanotubes Constructed Using Native Protein Structures: The Key Role of Flexible Linkers
Protein & Peptide Letters Brain Structural Abnormalities at the Onset of Schizophrenia and Bipolar Disorder: A Meta-analysis of Controlled Magnetic Resonance Imaging Studies
Current Pharmaceutical Design The Potential of Serratiopetidase and Lumbrokinase for the Degradation of Prion Peptide 106-126 - an <i>In Vitro</i> and <i>In Silico</i> Perspective
CNS & Neurological Disorders - Drug Targets The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Current Topics in Medicinal Chemistry Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies
Current Topics in Medicinal Chemistry Early Expression of Neuronal Dopaminergic Markers in a Parkinson’s Disease Model in Rats Implanted with Enteric Stem Cells (ENSCs)
CNS & Neurological Disorders - Drug Targets Docking Studies for Multi-Target Drugs
Current Drug Targets Magnetic Materials for the Selective Analysis of Peptide and Protein Biomarkers
Current Medicinal Chemistry Preface: Developments in Understanding of Alzheimer Disease
Current Alzheimer Research Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds
Current Pharmaceutical Design Molecular Biology, Pharmacology and Functional Role of the Plasma Membrane Dopamine Transporter
CNS & Neurological Disorders - Drug Targets Multi-Target Compounds Acting in the Central Nervous System Designed From Natural Products
Current Medicinal Chemistry Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design
Current Neuropharmacology Meet Our Editorial Board Member
Current Neuropharmacology VEGF Signaling Regulates Cofilin and the Arp2/3-complex within the Axonal Growth Cone
Current Neurovascular Research Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology Late Onset Alzheimer’s Disease: Novel Clinical Prospects for the Future
Current Neurovascular Research Upregulation of Suppressor of Cytokine Signaling 3 in Microglia by Cinnamic Acid
Current Alzheimer Research Diversified Thiazole Substituted Coumarins and Chromones as Non- Cytotoxic ROS and NO Inhibitors
Letters in Drug Design & Discovery